



Pharmaceutical Services, 2 Franklin Street, Belfast BT2 8DQ
Telephone No. 028 95 36 0333

Medicine Supply Notification: Edoxaban (Lixiana®) 15mg tablets

Tier 2 – medium impact

Date of issue: 01/09/2026

[Medicines Supply Tool – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice](#)

Summary

- Edoxaban (Lixiana®) 15mg tablets are out of stock until mid-September 2026.
- Alternative direct-acting oral anticoagulants (DOACs) remain available and can support increased demand.
- Unlicensed supplies of edoxaban 15mg tablets may be sourced, lead times vary.

ACTIONS REQUIRED

Clinicians should not initiate new patients on edoxaban 15mg tablets until the shortage resolves. Where patients have insufficient supply to last until the resupply date, clinicians should:

- review patients to determine if use is for the licensed indication or for an off-label use,
- consider appropriateness of switching to an alternative DOAC;
- where the above option is not suitable, consider prescribing unlicensed edoxaban 15mg tablets; prescribers should work with pharmacy teams to ensure orders are placed within appropriate time frames as lead times may vary (see Supporting information below).

If there is uncertainty over selection of an alternative anticoagulant or if the above options are not considered appropriate, clinicians should seek advice and guidance from the anticoagulation team.

Supporting information

Clinical Information

Edoxaban 30mg film coated tablets are not scored. The manufacturer has no data available demonstrating the safety or efficacy of edoxaban tablets which have been split prior to administration. Although the tablets are licensed to be crushed and mixed with water, this is only suitable for delivering a whole dose.

Edoxaban 15mg is not licensed for use as monotherapy, as it may result in decreased efficacy. It is only licensed for use in switching from edoxaban 30mg (dose used in patients with ≥ 1 clinical factors for increased exposure) to a vitamin K antagonist (e.g. warfarin). Edoxaban 15mg and warfarin are taken together, and once an INR ≥ 2.0 is achieved, edoxaban is discontinued. The SPC notes most patients (85%) should be able to achieve an INR ≥ 2.0 within 14 days of concomitant administration and after 14 days it is recommended that edoxaban is discontinued and warfarin continued to be titrated to achieve an INR between 2 and 3. The alternative to edoxaban 15mg in this setting is to discontinue 30mg edoxaban and use a parenteral anticoagulant with warfarin at the time of the next scheduled edoxaban dose. Once a stable INR of ≥ 2.0 is achieved, the parenteral anticoagulant is discontinued and warfarin continued.

There may be off label use of edoxaban 15mg, for example, in elderly patients considered ineligible for standard doses of oral anticoagulants because of their high bleeding risks.

Links to further information

- BNF - Edoxaban [Edoxaban | Drugs | BNF | NICE](#)
- SmPC - Edoxaban (Lixiana®) 15mg tablets [Lixiana 15mg Film-Coated Tablets - Summary of Product Characteristics \(SmPC\) - \(emc\) | 6907](#)

Guidance on ordering and prescribing unlicensed imports

The following specialist importers have confirmed they can source unlicensed edoxaban 15mg tablets. Please note there may be other companies that can also source supplies:

- BAP Pharma
- Chemys
- Clinigen
- Eaststone
- Mawdsleys
- Target

Any decision to prescribe an unlicensed medicine must consider the relevant guidance and NHS Trust or local governance procedures. Unlicensed imports do not undergo any central quality assessment or suitability evaluation. Therefore, any import must be locally assessed in line with local unlicensed medicines processes.



Please see the links below for further information:

- The supply of unlicensed medicinal products, Medicines and Healthcare products Regulatory Agency (MHRA) [The supply of unlicensed medicinal products special GN14.pdf](#)
- Professional Guidance for the Procurement and Supply of Specials, Royal Pharmaceutical Society [RPS publishes updated guidance for the procurement and supply of specials - The Pharmaceutical Journal](#)
- Prescribing unlicensed medicines, General Medical Council (GMC) [Prescribing unlicensed medicines - professional standards - GMC](#)

When prescribing a product that is not licensed in the UK due to a supply issue with the licensed alternative prescribers must indicate on the HS21 prescription that an unlicensed product is required, with the following wording: “special order”